Tight GDM Targets Work
A recent clinical study found that adopting tight glycemic targets in gestational diabetes cut the risk of large‑for‑gestational‑age births without increasing serious maternal or neonatal complications — a clear win for precision glucose targets in pregnancy. That result reinforces the value of close monitoring and data‑driven target setting in gestational care Tight Glycemic Target in Gestational Diabetes Reduces Risks | Medscape.
A single‑center, open‑label randomized controlled trial enrolled 650 pregnant women with GDM and randomized them to tight (fasting <5.1 mmol/L; 1‑hour <7.0 mmol/L) versus less‑tight (fasting <5.3 mmol/L; postprandial <7.8 mmol/L) glycaemic targets ([arxivlens.com)]. Of 650 enrolled, 626 (96.3%) completed primary‑outcome follow‑up and the trial reported large‑for‑gestational‑age (LGA) rates of 19.2% with tight targets versus 26.5% with less‑tight targets (adjusted RR 0.61; 95% CI 0.42–0.89; p=0.010). (arxivlens.com) The same trial found lower cesarean delivery rates with tight targets (23.0% vs 29.9%; adjusted RR 0.63; p=0.012) and a modest reduction in mean gestational weight gain (10.1 kg vs 10.7 kg; p=0.006). (arxivlens.com) Tight targets required more insulin (32.6% vs 21.6%; adjusted RR 1.67; p=0.005), while rates of serious neonatal events and maternal hypoglycaemia remained low and similar between arms, according to the trial report. (arxivlens.com) Those new single‑center results differ from the multicentre TARGET stepped‑wedge trial of 1,100 women in New Zealand, which found no significant LGA difference (14.7% vs 15.1%; aRR 0.96; p=0.839) and was conducted across 10 hospitals between May 29, 2015 and Nov 7, 2017. (thelimbic.com) A post‑hoc 4.5‑year follow‑up of the TARGET cohort (315 mothers, 313 children assessed) reported similar maternal HbA1c and child BMI but higher rates of coordination difficulties (28.4% vs 17.8%; adjRR 1.66) and signals of autism‑spectrum‑type behaviour (9.3% vs 2.6%; adjRR 3.67) in the tight‑target group. (journals.plos.org) Authors of the new randomized trial and the TARGET follow‑up explicitly called for replication in other populations and longer‑term neurodevelopmental surveillance before broad changes to guideline glycaemic thresholds are adopted. (diabetesresearchclinicalpractice.com)
